Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review

The fully human monoclonal antibody denosumab was approved for treatment of osteoporosis in 2010 on the basis of its potent antiresorptive activity, which produces clinically meaningful increases in bone mineral density (BMD) and reduces fracture risk at key skeletal sites. At that time, questions r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kendler, David L., Cosman, Felicia, Stad, Robert Kees, Ferrari, Serge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799550/
https://www.ncbi.nlm.nih.gov/pubmed/34762286
http://dx.doi.org/10.1007/s12325-021-01936-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799550/
https://www.ncbi.nlm.nih.gov/pubmed/34762286
http://dx.doi.org/10.1007/s12325-021-01936-y

Ejemplares similares